GlassScriptPhysician profile
Laura R Collins
NPI 1134219629
$1,910.15
in general payments reported to CMS, 2019-2025
28 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $213 · 2021: $418 · 2022: $183 · 2023: $290 · 2024: $329 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $492.67 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $160.95 | 2022-2025 | Novasure, Fluent Fluid Management System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Mayne Pharma Commercial LLC | $147.94 | 2022-2025 | |
| Astellas Pharma US INC | $144.96 | 2023-2025 | Veozah |
| Organon LLC | $124.81 | 2021-2024 | Nexplanon |
| Exeltis, USA INC. | $113.51 | 2021-2025 | Slynd |
| Pacira Pharmaceuticals Incorporated | $98.26 | 2023 | Exparel |
| Bayer Healthcare Pharmaceuticals INC. | $94.79 | 2019-2022 | |
| Baxter Healthcare | $83.02 | 2024 | Perclot |
| Pfizer INC. | $65.97 | 2019-2022 | |
| Minerva Surgical, INC | $49.15 | 2024 | |
| Myovant Sciences INC. | $36.70 | 2021-2022 | |
| Roche Diagnostics Corporation | $32.64 | 2019 | |
| Biogen, INC. | $25.47 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $24.77 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.59 | 2019-2020 | |
| Medtronic, INC. | $22.76 | 2024 | Ligasure |
| Applied Medical Resources Corporation | $20.72 | 2022 | |
| Millicent US INC | $18.73 | 2025 | Femlyv, Intrarosa |
| Kci USA, INC. | $18.52 | 2023 | Prevena |
| Meditrina | $18.33 | 2023 | |
| Avanos Medical | $17.84 | 2019 | |
| Sumitomo Pharma America, INC. | $13.71 | 2025 | Myfembree |
| Therapeuticsmd, INC. | $13.52 | 2019 | |
| Convatec INC. | $12.79 | 2019 | |
| Agile Therapeutics, INC. | $11.73 | 2022 | |
| Evofem Biosciences, INC. | $11.16 | 2021 | |
| Merck Sharp & Dohme LLC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.